Literature DB >> 11301922

Management of anxiety disorders: the added challenge of comorbidity.

D L Dunner1.   

Abstract

Patients with anxiety present with a wide variety of disorders that cause significant impairment to their everyday lives. To complicate matters, patients seldom present with just one anxiety disorder. Such comorbidity, particularly where depression is also present, has important implications for both the patient and the physician. The patient typically suffers from a greater degree of everyday impairment, is more reliant on healthcare services, in particular mental health services, and may be at a greater risk of attempting suicide. For the physician, comorbidity in anxiety disorders presents a challenge as the patient's symptoms are often more severe, present earlier in life, and are frequently prolonged which makes their management more complex. This review will focus on the anxiety disorders: panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorder. The impact of co-existing multiple anxiety disorders, depression, or a history of substance abuse will be discussed with a view to choosing the appropriate management strategy. Treatment options will be reviewed.

Entities:  

Mesh:

Year:  2001        PMID: 11301922     DOI: 10.1002/da.1018

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  7 in total

Review 1.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

2.  Treating depression and anxiety in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder.

Authors:  Sonya B Norman; Ursula S Myers; Kendall C Wilkins; Abigail A Goldsmith; Veselina Hristova; Zian Huang; Kelly C McCullough; Shannon K Robinson
Journal:  Neuropharmacology       Date:  2011-05-13       Impact factor: 5.250

4.  Regulatory mechanisms of fear extinction and depression-like behavior.

Authors:  Natalie C Tronson; Christina Schrick; Andre Fischer; Farahnaz Sananbenesi; Gilles Pagès; Jacques Pouysségur; Jelena Radulovic
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

5.  Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Authors:  Ruth Ann Marrie; Carol A Hitchon; Randy Walld; Scott B Patten; James M Bolton; Jitender Sareen; John R Walker; Alexander Singer; Lisa M Lix; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-05-21       Impact factor: 4.794

6.  Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.

Authors:  Lucia Recinella; Annalisa Chiavaroli; Giustino Orlando; Claudio Ferrante; Serena Veschi; Alessandro Cama; Guya Diletta Marconi; Francesca Diomede; Iacopo Gesmundo; Riccarda Granata; Renzhi Cai; Wei Sha; Andrew V Schally; Luigi Brunetti; Sheila Leone
Journal:  Mol Psychiatry       Date:  2021-07-30       Impact factor: 15.992

Review 7.  PTSD and comorbid AUD: a review of pharmacological and alternative treatment options.

Authors:  Elizabeth Ralevski; Lening A Olivera-Figueroa; Ismene Petrakis
Journal:  Subst Abuse Rehabil       Date:  2014-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.